Welcome to 4SC
4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases in indications with high unmet medical needs. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development and in early-stage research. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical and biotechnology companies.
4SC AG is listed on the Frankfurt Stock Exchange (Prime Standard: VSC/ISIN DE0005753818), Germany.
4SC’s lead compound in autoimmune diseases generates a response rate of 88.5% for the treatment of patients with Crohn's disease and ulcerative colitis... more
Sign up to receive press releases and financial reports... more